Analyst Price Target is $39.60
▲ +19.53% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Revance Therapeutics in the last 3 months. The average price target is $39.60, with a high forecast of $65.00 and a low forecast of $24.00. The average price target represents a 19.53% upside from the last price of $33.13.
Current Consensus is
Buy
The current consensus among 7 investment analysts is to buy stock in Revance Therapeutics. This Buy consensus rating has held steady for over two years.
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.
Read More